Longevity Supplement Candidates: The Second Tier, Audited
Past the Big Five, the supplement shelf gets murkier and the marketing louder. This page audits the six names that dominate longevity podcasts: glycine, berberine, CoQ10, ashwagandha, astaxanthin, and resveratrol — the evidence for each, the doses trials actually used, and, because every active compound has a cost, the side effects and interactions nobody prints on the bottle.
What the evidence supports
- Glycine (3 g pre-bed) improved subjective sleep quality in small Japanese crossover RCTs — real trials, small, industry-funded.
- Berberine lowers fasting glucose and HbA1c in meta-analysis — metformin-territory numbers built on mostly low-quality trials.
- CoQ10 shows a modest systolic blood-pressure reduction (~−4.8 mmHg in meta-analysis) and signals in heart failure (Q-SYMBIO, n=420).
- Ashwagandha reduces perceived stress and cortisol in multiple small RCTs — with a rare-but-real liver-injury flag.
What remains uncertain
- Astaxanthin's skin evidence rests on small, short, largely industry-funded trials.
- Resveratrol hits a bioavailability wall — null blood-pressure meta-analyses and a null large metabolic trial.
- Long-term safety data are thin across the whole tier.
Evidence last reviewed: September 16, 2026. Conclusions may change as new research is published.
the second tier, audited
Product picks are generic categories, not brands. We may earn a commission on Amazon or iHerb purchases at no cost to you — this never changes our evidence conclusions. Full disclosure
Glycine powder
The sleep-trial molecule: 3 g before bed in the small crossover studies.
⚠️ Sweet-tasting; industry-funded evidence base; not an insomnia treatment.
Check price on Amazon →Why a Second Tier Exists
The Big Five earned their slot by clearing a bar: hundreds of trials, or correction of a measurable deficiency, or both. The supplements below don't clear it. They have plausible mechanisms, trials that number in the dozens, and modest effect sizes even when the trials agree. That's what "second tier" means here — not "worthless," and not "the next creatine." Set expectations before the ledger: everything on this page sits at two to three stars of evidence. The best of the tier is moderate; none of it approaches the first tier's support. (NAD+ precursors like NMN, the seventh name on the influencer list, are deliberately deferred — the weakest human evidence of all, a biomarker-only story so far.)
The Ledger: Six Candidates at a Glance
This table is the page. Read it the way an auditor would: what the trials showed, what it seemed to do, and what it cost — on this site, no benefit is ever presented without its cost.
| Supplement | Human evidence | Best-supported use | Main watch-items (side effects / interactions) | Verdict |
|---|---|---|---|---|
| 🌙 Glycine | Small crossover RCTs (n≈11–58, Japan, Ajinomoto-funded) on subjective sleep quality (Yamadera 2007; Inagawa 2006) | Pre-bed sleep quality — subjective, not dramatic | Sweet taste; GI upset at high doses; industry-funded, small evidence base | ★★★☆☆ Moderate |
| 🌿 Berberine | 37-trial glucose meta-analysis: FPG −0.82 mmol/L, HbA1c −0.63% (Xie 2022) — pooled from mostly low-quality trials | Glucose-lowering adjunct territory — conversations, not substitutions | CYP3A4/2D6/2C9 interactions (cyclosporine, statins, many drugs); GI upset and constipation; contraindicated in pregnancy; hypoglycemia risk with diabetes medications | ★★★☆☆ Moderate* |
| ⚡ CoQ10 | Blood-pressure meta-analysis (~−4.8 mmHg systolic; Moradi 2022); Q-SYMBIO (n=420) in heart failure (Mortensen 2014) | Blood-pressure and heart-failure adjunct discussions | Late-day dosing can disturb sleep; mild GI upset; may add to blood-pressure medication effects; warfarin caution | ★★★☆☆ Moderate |
| 🌰 Ashwagandha | Multiple small stress/cortisol RCTs, generally consistent direction | Stress and sleep support | Rare but real liver injury (26-case review including one transplant; TGA 2024 safety alert); thyroid stimulation; adds to sedatives; avoid in pregnancy | ★★★☆☆ Moderate ⚠️ |
| 🦐 Astaxanthin | Small skin trials (4–12 mg, 8–16 weeks), largely industry-funded; meta-analysis exists (Nutrients 2021) | Skin endpoints — elasticity, wrinkles, moisture | Orange skin discoloration at high doses; insufficient pregnancy data | ★★☆☆☆ Preliminary |
| 🍇 Resveratrol | Null blood-pressure meta-analysis (Liu 2014); the bioavailability wall (Walle 2004); STEP null on metabolic endpoints | Mostly a lesson in hype versus evidence | High-dose GI effects; possible kidney signal at 2.5–3 g/day (STEP); CYP interactions theoretical | ★★☆☆☆ Preliminary |
How to read this table: the stars rate the quality of the human evidence, never the size of the promise. The watch-items column is not a footnote; it exists because every biologically active compound has a cost, and marketing prints the benefit in large type and the cost in none. *Berberine's asterisk is the whole lesson of this page: its headline meta-analysis (Xie et al., 2022, PMID 36467075) pools 37 mostly low-quality trials, and Dong's earlier one (2012) reads the same way. Volume is not quality — see the chart below.
What "Moderate" Actually Means
This page is where the middle of the site's star system lives. Five stars is creatine territory — hundreds of trials, consistent results, clean safety data; four is strong cohorts with fewer trials. Three stars — "moderate" — means consistent small randomized trials: real blinding and placebo arms, but samples you can count without a calculator, durations of weeks, and endpoints that are often subjective. Two stars — "preliminary" — means early, mixed, or industry-shaped evidence where the next well-run trial could flip the sign.
The chart's quiet joke is glycine: five small trials carry the same podcast weight as berberine's forty — when you hear "well-studied," ask studied how well.
The Pattern in the Watch-Items Column
Read down the fourth column of the ledger and a pattern appears: the safety data are thinner than the efficacy data, for every row. Small trials are powered to detect whether a compound does something; they cannot catch uncommon harms. A trial of 40 people can show a supplement lowers cortisol; it would need tens of thousands to detect a one-in-ten-thousand liver injury. Ashwagandha's liver flag came not from trials but from case reports — 26 cases across 19 studies in one systematic review (Egyptian Journal of Internal Medicine, 2026), including one patient who needed a transplant, plus a parallel review of 25 patients (Cureus, 2025). Australia's Therapeutic Goods Administration issued a formal safety alert in February 2024. None of that was visible in the stress RCTs that made the supplement famous.
- 🌿 "Natural" is not a safety rating — berberine is a plant alkaloid that inhibits CYP3A4, CYP2D6, and CYP2C9, liver enzymes that clear many prescription drugs. That is drug-class behavior and deserves drug-class respect.
- 📋 Adverse events are under-reported — supplements sit outside the active surveillance that catches drug harms; case reports and regulator alerts lag years behind the marketing.
- 🏥 "Well-tolerated in trials" is a small-sample statement — it means no harm appeared above the trial's detection floor, not that none exists.
The Doses Trials Actually Used
Doses below describe the literature, not recommendations — they're here so any conversation with a clinician starts from what was actually studied, not a marketer's scoop size.
| Supplement | Doses used in trials | Context worth knowing |
|---|---|---|
| 🌙 Glycine | 3 g before bed | A single pre-bed dose; effects on subjective quality and next-day alertness |
| 🌿 Berberine | ~1–1.5 g/day, divided 2–3 times | Divided dosing limits GI upset; the meta-analysis effect (−0.63% HbA1c) sat here |
| ⚡ CoQ10 | 100–300 mg/day | Fat-soluble — take with a meal; the ~−4.8 mmHg average came from this range |
| 🌰 Ashwagandha | 300–600 mg/day of standardized root extract | The stress/cortisol RCT range; more is not the studied direction |
| 🦐 Astaxanthin | 4–12 mg/day | The skin-trial range (8–16 weeks); discoloration reports sit at the high end and above |
| 🍇 Resveratrol | 150–500 mg/day in most trials | Far above dietary intake; STEP's kidney signal appeared at 2.5–3 g/day |
⚠️ Doses are descriptions, not prescriptions
Nothing on this page tells you to take anything. If you take prescription medications, are pregnant or planning to be, or manage a chronic condition, the dosing conversation belongs with a clinician who can see your full list. Never start, stop, or change a medication to accommodate a supplement.
Who Should Be Extra Careful
- 🤰 Pregnancy or planning it — berberine is contraindicated; ashwagandha is advised against; astaxanthin has insufficient pregnancy data. This tier is simply not worth it here.
- 🩸 Liver disease or a history of it — ashwagandha's case-report literature puts it off the table without specialist sign-off.
- 💉 Diabetes medications — berberine adds glucose-lowering on top of them (hypoglycemia risk); CoQ10 can add to blood-pressure medication effects. Clinician territory in both cases.
- 🧪 Warfarin or anticoagulants — CoQ10 carries a long-standing warfarin caution; treat the combination as a prescriber conversation, not a bottle label.
- 🏥 Upcoming surgery — ashwagandha adds to sedatives and berberine's enzyme interactions matter for anesthetic drugs; standard practice is stopping them well before an operation, on the surgical team's timeline.
Product picks are generic categories, not brands. We may earn a commission on Amazon or iHerb purchases at no cost to you — this never changes our evidence conclusions. Full disclosure
CoQ10
The most medically grounded of the tier — 100–300 mg/day in BP and heart-failure research.
⚠️ Late-day doses can disturb sleep; clinician check on BP or blood-thinning medication.
Check price on Amazon →Product picks are generic categories, not brands. We may earn a commission on Amazon or iHerb purchases at no cost to you — this never changes our evidence conclusions. Full disclosure
Ashwagandha root extract
300–600 mg/day of root extract in the stress RCTs — with a real liver caution label.
⚠️ Rare liver-injury reports; avoid in pregnancy and liver disease.
Check price on Amazon →The Bottom Line
- This is a 2–3 star tier — the best of it (glycine, berberine, CoQ10, ashwagandha) is "moderate," and the rest is preliminary; nothing here is first-tier.
- Read the watch-items column first — berberine's enzyme interactions and ashwagandha's liver flag are real costs, not fine print.
- Trial volume is not trial quality — forty low-quality trials can out-count five good ones and still mean less.
- The fundamentals outrank the whole tier — nothing here outperforms the Big Five, protein, and fiber; on any medication, involve a clinician first.
Go Deeper: Longevity Supplement Candidates
Each candidate gets its own full audit — trial detail, dosing, and the interactions that matter on prescription drugs.
- 🔗 Glycine: the 3-gram sleep candidate — the small Japanese crossover trials and the industry funding behind them. Read it →
- 🔗 Berberine: the plant that behaves like a drug — metformin-territory numbers on low-quality trials, and the CYP interactions. Read it →
- 🔗 CoQ10: the mitochondrial audit — the blood-pressure meta-analysis, Q-SYMBIO, and the warfarin caution. Read it →
- 🔗 Ashwagandha: stress evidence and the liver flag — the stress RCTs beside the 26-case liver review and the TGA alert. Read it →
- 🔗 Astaxanthin: skin-deep evidence — the industry-funded skin trials and where the meta-analysis stops. Read it →
- 🔗 Resveratrol: the bioavailability problem — null metas, the metabolized-too-fast wall, and STEP's kidney signal. Read it →
Related Topics
- Yamadera W et al., "Glycine ingestion improves subjective sleep quality," Sleep and Biological Rhythms (2007)
- Inagawa K et al., "Subjective effects of glycine ingestion before bedtime," Sleep and Biological Rhythms (2006)
- Xie X et al., "Glucose-lowering effect of berberine on type 2 diabetes: A systematic review and meta-analysis," Frontiers in Pharmacology (2022; PMID 36467075)
- Dong H et al., "Berberine in the treatment of type 2 diabetes mellitus: a systemic review and meta-analysis," Evidence-Based Complementary and Alternative Medicine (2012)
- Mortensen SA et al., "The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure: Q-SYMBIO," JACC: Heart Failure (2014)
- Kennedy C, Köller Y, Surkova E., "Effect of Coenzyme Q10 on statin-associated myalgia: systematic review and meta-analysis," Atherosclerosis (2020)
- Moradi M et al., "CoQ10 supplementation and blood pressure: dose-response meta-analysis" (2022; PMID 36130103)
- "Ashwagandha-induced liver injury: a systematic review of case reports," Egyptian Journal of Internal Medicine (2026)
- "Ashwagandha-Associated Liver Injury: A Scoping Review," Cureus (2025)
- Therapeutic Goods Administration (Australia), safety alert on Withania somnifera products (February 2024)
- "Systematic Review and Meta-Analysis on the Effects of Astaxanthin on Human Skin Ageing," Nutrients (2021)
- Liu Y et al., "Effect of resveratrol on blood pressure: a meta-analysis of randomized controlled trials," Clinical Nutrition (2014)
- Walle T et al., "High absorption but very low bioavailability of oral resveratrol in humans," Drug Metabolism and Disposition (2004)